Previous 10 | Next 10 |
Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced...
Approximately $16.3 million in Common Shares Sold Under At-the-market Agreement Used to Offset Prepayment of Debt Second Amendment to $30 Million Term Loan Provides Additional Financial Flexibility for Growth Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven d...
Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company’s board of directors. Dr. Kayyem’s diverse career spans more than 20 years and includes expe...
Biodesix (NASDAQ:BDSX) and Spesana have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the U.S. utilizing Spesana’s digital platform solutions for comprehensive lung cancer management. Spesana is a cloud based Digital Hea...
Spesana , the developer of a novel electronic operating system to unify EMRs, and Biodesix Inc. (NSDQ: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that they have partnered to further streamline and automate the use of m...
Data published shows the VeriStrat proteomic test improved overall patient survival by better informing physicians on the selection of immunotherapies to optimally treat NSCLC patients Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company wit...
Image source: The Motley Fool. Biodesix, Inc. (NASDAQ: BDSX) Q3 2021 Earnings Call Nov 15, 2021 , 9:00 a.m. ET Operator Continue reading For further details see: Biodesix, Inc. (BDSX) Q3 2021 Earnings Call Transcript
The following slide deck was published by Biodesix, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Biodesix, Inc. 2021 Q3 - Results - Earnings Call Presentation
Biodesix, Inc. (BDSX) Q3 2021 Earnings Conference Call November 15, 2012, 9:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - President and Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley...
Third Quarter 2021 Lung Diagnostic Revenue of $4.5 Million Increased 51% over Third Quarter 2020 Company launches 72-hour Next Generation Sequencing (NGS) test Conference Call and Webcast Today at 9:00 a.m. ET Biodesix, Inc. (Nasdaq: BDSX), a leading data...
News, Short Squeeze, Breakout and More Instantly...
Awarding Excellence in Company Culture Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list . The ranking is a result of a comprehensive, data-driven measurement pro...
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William Blair 44 th Annual Growth Stock Conference Presentation and 1x1...
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced that new data will be presented today at the 2024 American Thoracic Society ...